Inactive Instrument

Sanofi SA Share Price Nyse

Equities

US80105N1054

Pharmaceuticals

Financials

Sales 2024 * 46.24B 49.76B 3,967B Sales 2025 * 49.92B 53.73B 4,283B Capitalization 114B 123B 9,780B
Net income 2024 * 7.13B 7.67B 612B Net income 2025 * 8.66B 9.32B 743B EV / Sales 2024 * 2.61 x
Net Debt 2024 * 6.56B 7.06B 563B Net Debt 2025 * 1.95B 2.1B 167B EV / Sales 2025 * 2.32 x
P/E ratio 2024 *
16.1 x
P/E ratio 2025 *
13.2 x
Employees -
Yield 2024 *
4.21%
Yield 2025 *
4.46%
Free-Float 87.12%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 56 31/08/19
Chief Operating Officer 40 31/12/21
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 30/04/14
Director/Board Member 64 21/05/20
Chairman 60 01/09/22
More insiders
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company